Skip to main content
Take the Quiz

A system personalized to you

When you turn to DBS, you’re taking control of your Parkinson's disease (PD) diagnosis. This is a brave decision backed by research, conversations with family, doctors, and loved ones. We don’t take your interest in Boston Scientific lightly and want to demonstrate the differences in our DBS solution, so you can make an informed decision about your care.

Combining Multiple Independent Current Control (MICC) and novel directional capabilities, the Vercise Genus™ DBS System offers unprecedented control for improved patient outcomes.

The Boston Scientific difference

Boston Scientific’s Vercise™ Directional DBS Systems* provide your doctor sensitive and precise ways to manage your needs and adapt as your symptoms change over time.

Our MICC technology makes us uniquely capable of delivering precise therapy by pairing directional leads with a stimulator that independently powers each electrode on the lead. Our Image Guided Programming enables your physician to see the exact location of your leads and deliver personalized therapy to you. Regardless of how your symptoms change over time, your Boston Scientific DBS system will follow and create more opportunities for your therapy to be effective.1

Note: Stimulation using multiple independent current control (MICC) with a Direcitonal Lead is referred to as Cartesia™ 3D

The science behind our systems

At Boston Scientific, research and clinical evidence are vital to how we make decisions, evaluate our technology, and continue to advance our field. Accordingly, we conducted a multicenter, prospective, double blinded, randomized, trial for those living with DBS at their one-year follow-up, called the INTREPID study.2

1 year into treatment, Boston Scientific DBS patients experienced a 51% improvement in their motor function2

At the end of 1 year, the Boston Scientific patient achieved 6 additional hours of good quality "ON time" each day, compared to their best treatment before DBS2

DBS patients with a Boston Scientific system experienced meaningful improvements in their quality of life2

1 year into treatment, Boston Scientific DBS patients reported a 30% decrease in medication usage2

See how Directional DBS targets your PD symptoms

Charging your life

Many DBS devices require a surgery to replace the battery every 3-5 years.3 Our rechargeable battery Vercise Genus R16 System is warrantied for up to 15 years.

Unparalleled comfort

Both of our Vercise Genus™ DBS Systems have gently contoured edges for comfort. The Vercise Genus P16 System is the thinnest non-rechargeable battery available.

Vercise Genus™ R16 System

  • Smallest DBS stimulator
  • Rechargeable
  • Warrantied for up to 15 years
  • Powered by Cartesia™ 3D technology
  • Bluetooth® wireless remote connectivity**
  • Full body MRI access***

Vercise Genus™ P16 System

  • Thinnest, non-rechargeable, dual channel DBS Stimulator
  • Lasts a minimum of 3 years with nominal settings
  • Powered by Cartesia 3D technology
  • Bluetooth® wireless remote connectivity**
  • Full body MRI access***

Note: Stimulation using multiple independent current control (MICC) with a Directional Lead is referred to as Cartesia 3D

Hear from the experts

Dr. Jerold Vitek, Professor and Chair, Department of Neurology, University of Minnesota, talks about the difference of the Vercise™ DBS System.

Help us connect you to the right resources and specialists.

Answer a few short questions. Take the quiz now. ⟶

References: 1. Eleopra R, Rinaldo S, Devigili G, et al. Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients. Clin Neurophysiol. 2019;130(9):1562-1569. doi:10.1016/j.clinph.2019.06.001 2. Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson’s disease (INTREPID): a multicenter, double-blind, randomised, sham-controlled study. Lancet Neurology. 2020;19(6):491‐501. doi:10.1016/S1474-4422(20)30108-3 3. Qiu, X., Wang, Y., Lin, Z., Wu, Y., Xu, W., Wu, Y., Sun, B., Ashkan, K., Zhang, C., & Li, D. (2021). Fixed-Life or Rechargeable Batteries for Deep Brain Stimulation: Preference and Satisfaction Among Patients With Hyperkinetic Movement Disorders. Frontiers in neurology, 12, 662383. https://doi.org/10.3389/fneur.2021.662383

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

*A System that includes the Vercise™ PC, Vercise Gevia™, or Vercise Genus™ IPG and Vercise Cartesia™ Directional Lead(s) forms the Vercise Directional System.

**The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Boston Scientific Neuromodulation Corporation is under license.

***MR Conditional when all conditions are met

The Vercise Genus™ DBS System, Vercise Genus Mixed System with M8 Adapter, Vercise Gevia™ DBS System, and Vercise™ DBS Lead-only system (before Stimulator is implanted) provide safe access to full-body MRI scans when used with specific components and the patient is exposed to the MRI environment under specific conditions defined in the supplemental manual ImageReady™ MRI Guidelines for Boston Scientific DBS Systems.

Indication for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
-Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
-Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. 
-Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability.

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications: The Boston Scientific Deep Brain Stimulation (DBS) Systems are not recommended for patients who will be exposed to the following procedures: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS).  The safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established.  Patients implanted with Boston Scientific DBS Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with the Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems.  Boston Scientific DBS Systems are not recommended for patients who are unable to operate the system or are poor surgical candidates or who experience unsuccessful test stimulation.

Warnings: Unauthorized modification to the medical devices is prohibited.  You should not be exposed to high stimulation levels.  High level of stimulation may damage brain tissue.  Patients implanted with a Boston Scientific DBS System may be at risk for intracranial hemorrhages (bleeding in the brain) during DBS lead placement.  Strong electromagnetic fields, such as power generators, security screeners or theft detection systems, can potentially turn the stimulator off, or cause unpredictable changes in stimulation. The system should not be charged while sleeping.  If you notice new onset or worsening depression, changes in mood or behavior or impulse control, or have thoughts of suicide contact your physician or emergency services immediately.  Chemical burns may result if the Stimulator housing is ruptured or pierced.  The Boston Scientific DBS Systems may interfere with the operation of implanted stimulation devices, such as cardiac pacemakers, implanted cardioverter defibrillators, or medication delivery pumps. Patients should operate motorized vehicles or potentially dangerous machinery with caution.  It is unknown if the device may hurt an unborn baby. Your doctor may be able to provide additional information on the Boston Scientific DBS Systems.  For complete indications for use, contraindications, warnings, precautions, and side effects, see DBSandME.com or call 833-DBS-INFO or 833-327-4636.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.